Episode 253: Advances in Mutation-Driven Lung Cancer

Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies, as well as the expanding role of EGFR-, ALK-, BRAF-, and KRAS-targeted therapies in neoadjuvant and adjuvant settings. The conversation also examines the challenges of financial toxicity, decisions around adjuvant treatment cessation, and the nuanced management of locally advanced and stage IV EGFR-positive disease in the era of precision oncology.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA